The future of life sciences is in data, and no firm is better situated than MoFo to understand the convergence of the life sciences industry and data analytics. Our Life Sciences Group advises clients on all legal aspects of life sciences data analytics businesses, including patenting software and AI-related life science inventions, licensing of data, providing counsel on the steps to ensure data privacy and ethical use of data, and guiding clients through the FDA approval process for data-driven diagnostic assays and medical devices. Our Life Sciences Group is a unique amalgamation of lawyers with extensive training in biotechnology and pharmaceuticals coupled with the cutting-edge application of data science. We apply this combination for our digital health, biotechnology, medical device, pharmaceutical, and agtech clients, bridging the gap between the law and science.

Routinely recognized as a leading firm for life sciences and technology, we are uniquely qualified to understand how data is being used to gain insights and drive innovation in agriculture, medicine, and clinical research. We help our clients embrace analytics-driven insights and apply data-driven decision making to the most pressing issues they face in the marketplace, and we apply our fluency in data science and analytics to support our client’s goals to track execution against strategy.

We counsel more than 500 companies and research institutions, as well as the venture capital funds and investment banks that finance them, around the globe. We maintain an impressive reputation by representing leading life sciences and healthcare companies, as well as the investors that are driving the hottest innovations – from the world’s largest and most influential companies to ground-breaking entrepreneurs and start-ups. Across legal disciplines, our Life Sciences team works with companies at every phase of their growth cycle, from conception to commercialization and exit, vigilantly protecting and enforcing our clients’ rights.

Represented Alcon, the eye care division of Novartis, in a major collaboration with Google to develop and commercialize a glucose-sensing contact lens for use by diabetic patients, and an accommodating intraocular and contact lenses to restore the eye’s autofocus.
Strategic patent counseling and prosecution services for Genentech’s most difficult and challenging patent matters, including developing overall patent strategy, patent application drafting, and prosecution for key technologies.
Represent Gilead in various IP due diligence matters as well as provide strategic patent counseling and prosecution services for oncology and HIV treatments.
Edison Pharmaceuticals
Represented Edison Pharmaceuticals in a $4.29 billion strategic alliance with Dainippon Sumitomo Pharma Co., Ltd. for the development of drugs targeting cellular energy metabolism.
DaVita Inc.
Represented DaVita Inc. in its $4.42 billion acquisition of HealthCare Partners, LLC and its $3.05 billion acquisition of the U.S. renal care business of Gambro AB.
CNS Therapeutics
Represented CNS Therapeutics from its inception including through two venture financings, a loan facility, patent strategy, licensing and development agreements, critical manufacturing and supply agreements, trademark applications, and ultimately in its sale to the Mallinckrodt division of Covidien for $100 million.
Hanhai Investments Inc.
Advise the U.S. subsidiary of China’s largest operator of life sciences and high tech incubator facilities on the acquisition and development a biotech incubator campus on the San Francisco Peninsula.
Represented Terumo Corporation in its $2.6 billion acquisition of CaridianBCT from Sweden's Gambro AB.
Elan Pharma International Limited v. Abraxis BioScience
(District of Delaware). Represented Abraxis BioScience in defending its lead product, Abraxane, against claims by Elan Pharmaceutical of infringing Elan’s patents for coated nanoparticles used to deliver paclitaxel for the treatment of metastatic breast cancer. This was the first nanotechnology patent case taken to jury trial. The case settled in 2011.
Abbott Diabetes Care v. Roche Diagnostics Corp. and Bayer HealthCare LLC
(Northern District of California, Federal Circuit Court of Appeals). Represented Bayer HealthCare in one of the most significant patent cases in recent history. The Federal Circuit used the case to address the doctrine of inequitable conduct, which the court described as the “atomic bomb” of patent law because, if proved, it renders an entire patent (and sometimes related patents) unenforceable. The district court had agreed with Bayer that Abbott’s patent was unenforceable, and a three-judge panel of the Federal Circuit affirmed. The Federal Circuit heard the case en banc, affirmed Bayer’s overall victory in the case, and significantly altered the law of inequitable conduct (including adopting a number of changes urged by Bayer). More than 40 amicus briefs were filed, and the United States Patent and Trademark Office filed a brief and argued. On remand, Bayer again prevailed on inequitable conduct, even under the new, tougher standard.
Good Manufacturing Practices Investigation
Representing a former senior executive of a Fortune 500 health care and pharmaceutical company in connection with an investigation of the company’s good manufacturing practices (“GMP”) and recall of children’s medication.
Lethal Injection Matters
Worked with a major pharmaceutical company to stop the states of Missouri and Texas from using a significant anesthesia drug in their executions. Faced with the threat of litigation, both states chose alternative methods for lethal injection. Our work helped to prevent a catastrophic drug shortage, as the European Union, which publicly opposes executions and had previously banned the export of drugs used in lethal injections, threatened to impose export restrictions if this drug was used for executions anywhere in the United States.

U.S. News – Best Lawyers® Best Law Firms 2019
National: Biotechnology Law (Tier 1)
Los Angeles: Biotechnology Law (Tier 1)
San Diego: Biotechnology Law (Tier 1)
San Francisco: Biotechnology Law (Tier 1)

Chambers Global 2018
Global: Life Sciences
Asia-Pacific Region: Life Sciences

Chambers USA 2018
National: Life Sciences
California: Life Sciences

Chambers Asia Pacific 2019
Asia-Pacific Region: Life Sciences
Life Sciences (International Firms): China
Life Sciences (International Firms): Japan

Managing Intellectual Property Shortlist 2018
United States: Life Sciences IP Litigation

LMG Life Sciences 2017
Hatch-Waxman Patent Litigation
Patent Prosecution (Highly Recommended)
Patent Strategy and Management (Highly Recommended)

Here is what they say about us:

“Well placed, thanks to its global network, to provide IP and corporate support to biotech companies and leading investors on joint venture, funding, patent litigation and enforcement, and licensing issues in the life sciences sphere.” (Chambers Global 2018)

“noted for core technology expertise within the [life sciences] sector and an impressive transactional capability across the Asia-Pacific region.” (Chambers Global 2018)

“Top-notch lawyers who are client-focused and business savvy” (Chambers USA 2018)

“Solid teams in the USA and Asia offer broad expertise in transactions and IP work. Noted for its capabilities in capital markets transactions and is well known for patent matters, providing specialists for litigation and prosecution. Assists key international clients in the life sciences sector.”
(Chambers Global 2017)

“Clients say cases are run efficiently, effectively, with consideration of the budget and ultimately end up in an agreeable outcome.”
(Chambers USA 2017)

Read the latest legal and business insights impacting the global life sciences community

“Handles significant corporate transactions for leading life sciences clients, including M&A, strategic partnerships and IPOs. Also offers outstanding expertise in IP licensing and enforcement matters in the USA, with strong support from teams in Japan and China.”
(Chambers Global )

Recognized by U.S. News – Best Lawyers® Best Law Firms 2018 as a Tier 1 firm in biotechnology law.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.